1
|
Functional and pathological role of 15-Lipoxygenase and its metabolites in pregnancy and pregnancy-associated complications. Prostaglandins Other Lipid Mediat 2022; 161:106648. [PMID: 35577309 DOI: 10.1016/j.prostaglandins.2022.106648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2022] [Revised: 04/12/2022] [Accepted: 05/10/2022] [Indexed: 01/03/2023]
Abstract
Maternal lipid metabolism status during pregnancy may have pivotal effects on a healthy pregnancy, the progression of labor, and childbirth. Based on evidence, changes in maternal lipid profile and metabolism is related to various alterations in fetal metabolic status, fat mass, birth weight and can result in serious maternal and fetal complications. 15-lipoxygenase accounts as a key enzyme in metabolizing polyunsaturated fatty acids that generate various inflammatory lipid metabolites. The possible involvement of 15- lipoxygenase and its metabolites in the inflammatory process, cell proliferation and death, and immune response has been postulated. The indicative role of the 15- lipoxygenase enzymatic pathway in the implantation process, stages of pregnancy, embryogenesis, organogenesis, progression of labor, pregnancy period, and pregnancy-associated complications is remarkable. Accordingly, this study will review the research conducted on the role of 15- lipoxygenase in different reproductive tissues, and its pathological role in pregnancy-related diseases to provide more insight regarding the emerging role of 15-lipoxygenase in normal pregnancy.
Collapse
|
2
|
Fernández Peralbo MA, Priego-Capote F, Galache-Osuna JG, Luque de Castro MD. Targeted analysis of omega-6-derived eicosanoids in human serum by SPE-LC-MS/MS for evaluation of coronary artery disease. Electrophoresis 2014; 34:2901-9. [PMID: 24228265 DOI: 10.1002/elps.201200603] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A targeted approach has been applied to quantitative analysis of eicosanoids derived from omega-6 fatty acids in serum from individuals diagnosed with coronary artery disease (CAD). The target metabolites were series-2 prostaglandins, thromboxane B2, hydroxyeicosatetraenoic acids, and hydroxyoctadecadienoic acids. The method was based on SPELC-MS/MS in selected reaction monitoring mode for highly selective and sensitive determination of the target eicosanoids. The combination of SPE and LC-MS/MS involved the benefits from both direct analysis of serum without a step for protein precipitation and fully automation of the analysis. The method allowed comparison of omega-6-derived eicosanoids in serum from patients diagnosed with CAD and from control individuals. The effect of treatment with aspirin on the profile of the target compounds was evaluated through its incidence on the different pathways. Finally, the serum levels of the target metabolites in patients diagnosed with CAD were also statistically examined according to the severity of the coronary lesion stratified as stable angina, non-ST-elevation acute coronary syndrome, and acute myocardial infarction.
Collapse
|
3
|
Strassburg K, Huijbrechts AML, Kortekaas KA, Lindeman JH, Pedersen TL, Dane A, Berger R, Brenkman A, Hankemeier T, van Duynhoven J, Kalkhoven E, Newman JW, Vreeken RJ. Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in cardiac surgery. Anal Bioanal Chem 2012; 404:1413-26. [PMID: 22814969 PMCID: PMC3426673 DOI: 10.1007/s00216-012-6226-x] [Citation(s) in RCA: 188] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Revised: 06/21/2012] [Accepted: 06/22/2012] [Indexed: 10/28/2022]
Abstract
Oxylipins, including eicosanoids, affect a broad range of biological processes, such as the initiation and resolution of inflammation. These compounds, also referred to as lipid mediators, are (non-) enzymatically generated by oxidation of polyunsaturated fatty acids such as arachidonic acid (AA). A plethora of lipid mediators exist which makes the development of generic analytical methods challenging. Here we developed a robust and sensitive targeted analysis platform for oxylipins and applied it in a biological setting, using high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) operated in dynamic multiple reaction monitoring (dMRM). Besides the well-described AA metabolites, oxylipins derived from linoleic acid, dihomo-γ-linolenic acid, α-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid were included. Our comprehensive platform allows the quantitative evaluation of approximately 100 oxylipins down to low nanomolar levels. Applicability of the analytical platform was demonstrated by analyzing plasma samples of patients undergoing cardiac surgery. Altered levels of some of the oxylipins, especially in certain monohydroxy fatty acids such as 12-HETE and 12-HEPE, were observed in samples collected before and 24 h after cardiac surgery. These findings indicate that this generic oxylipin profiling platform can be applied broadly to study these highly bioactive compounds in relation to human disease.
Collapse
Affiliation(s)
- Katrin Strassburg
- Leiden Amsterdam Centre for Drug Research, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Annemarie M. L. Huijbrechts
- Department of Metabolic and Endocrine Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Kirsten A. Kortekaas
- Department of Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2-Dialyse BO-P, 2333 ZA Leiden, The Netherlands
| | - Jan H. Lindeman
- Department of General Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Theresa L. Pedersen
- USDA-ARS Western Human Nutrition Research Center, 430 West Health Sciences, Davis, CA USA
| | - Adrie Dane
- Leiden Amsterdam Centre for Drug Research, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Ruud Berger
- Department of Metabolic and Endocrine Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Arjan Brenkman
- Department of Metabolic and Endocrine Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Thomas Hankemeier
- Leiden Amsterdam Centre for Drug Research, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - John van Duynhoven
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
- Unilever Research and Development, Olivier van Noortlaan 120, 3133 AT Vlaardingen, The Netherlands
- Laboratory of Biophysics, Wageningen University, Dreijenlaan 3, 6703 HA Wageningen, The Netherlands
| | - Eric Kalkhoven
- Department of Metabolic and Endocrine Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - John W. Newman
- USDA-ARS Western Human Nutrition Research Center, 430 West Health Sciences, Davis, CA USA
- Department of Nutrition, University of California, 430 West Health Sciences, Davis, CA USA
| | - Rob J. Vreeken
- Leiden Amsterdam Centre for Drug Research, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
- Netherlands Metabolomics Centre, Einsteinweg 55, 2300 RA Leiden, The Netherlands
- Department of Analytical BioSciences, Leiden Amsterdam Centre for Drug Research, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| |
Collapse
|
4
|
Henke PK, Bergamini TM, Watson AL, Brittian KR, Powell DW, Peyton JC. Bacterial products primarily mediate fibroblast inhibition in biomaterial infection. J Surg Res 1998; 74:17-22. [PMID: 9536967 DOI: 10.1006/jsre.1997.5210] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE The stimulation of fibroblast growth is essential for the normal healing and tissue integration of biomaterials. The local elevation of proinflammatory mediators in infected perigraft fluid (PGF) may inhibit this growth. We sought to determine whether infected PGF inhibited fibroblast growth, and, if so, whether this was primarily dependent on the biomaterial, bacteria, or host. METHODS In vivo Dacron or expandable polytetra-fluoroethylene (ePTFE) grafts, sterile or colonized with slime-producing (RP-62A, viable or formalin-killed) or nonslime-producing (RP-62NA) Staphylococcus epidermidis (1 x 10(7) CFU/cm2), were implanted in Swiss Webster mice, and the PGF was harvested at 7 and 28 days. Antibodies to tumor necrosis factor alpha, interleukin 1 alpha, interferon gamma (7 micrograms/day), and indomethacin (50 micrograms/day) were administered by microinfusion pumps for 7 days and the PGF was harvested. Inhibition of the proinflammatory mediators was confirmed by enzyme-linked immunosorbant assay. The nontreated, heat-treated, or trypsin-digested in vivo PGF was incubated with an in vitro [3H]thymidine murine fibroblast (ATCC CCL-12) proliferation assay. RESULTS Fibroblast inhibition was significant at 7 and 28 days with infected PGF incubation compared with sterile and was not dependent on bacterial slime production or viability. Dacron sterile PGF did not significantly inhibit fibroblasts compared with control, whereas sterile ePTFE stimulated (P < 0.05) fibroblasts. Treatment of the PGF with proinflammatory cytokines, heat, and trypsin failed to reverse fibroblast inhibition in the infected state. CONCLUSION Biomaterial infection is associated with fibroblast inhibition that is dependent primarily on bacterial products and not the host or biomaterial. Conservative intervention strategies for graft infection need to address the problem of poor healing as well as bacterial clearance.
Collapse
Affiliation(s)
- P K Henke
- Department of Surgery, University of Louisville School of Medicine, Kentucky 40292, USA
| | | | | | | | | | | |
Collapse
|
5
|
Datta K, Kulkarni AP. Oxidative metabolism of aflatoxin B1 by lipoxygenase purified from human term placenta and intrauterine conceptal tissues. TERATOLOGY 1994; 50:311-7. [PMID: 7716738 DOI: 10.1002/tera.1420500406] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Aflatoxin B1 (AFB1) is a teratogen in rodents and may be a human transplacental carcinogen. Although the presence of DNA adducts of AFB1 in the human placentas has been noted, the enzyme(s) responsible for the bioactivation was not identified. In this investigation, the linoleic acid (LA)-dependent cooxidation of AFB1 catalyzed by lipoxygenase (LO) purified by Con A affinity chromatography from the term placentas of nonsmokers was studied. HPLC chromatograms detected the presence of 5- and 15-HETE as the major metabolites and 12-HETE as a minor metabolite upon incubation of arachidonic acid (AA) with affinity purified human term placental LO. These results suggest that a mixture of LO isozymes is present in the affinity-purified enzyme preparations of term placentas. The optimal assay conditions to observe maximum rate of epoxidation included incubation of 250 microM AFB1 with 80 micrograms LO and 3.5 mM LA at pH 7.2. AFB1-8,9-tris-diol produced in the reaction was estimated spectrofluorimetrically. A Vmax of 432 +/- 26 pmol of AFB1-8,9-tris diol produced/min/mg protein and a Km of 77 microM for AFB1 were observed. The AFB1-8,9-tris-diol formation was dependent on the incubation time, concentration of enzyme protein, AFB1, and LA. LO catalyzed epoxidation of AFB1 was inhibited by NDGA, BHT, BHA, ETI, and gossypol. The evidence presented here clearly demonstrates that placental LO is capable of epoxidation of AFB1. Similar results were observed with LO preparations of human intrauterine conceptal tissues at 8-10 weeks of gestation.
Collapse
Affiliation(s)
- K Datta
- Florida Toxicology Research Center, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa 33612
| | | |
Collapse
|